AMD campaign launched

Article

An AMD campaign has been launched by the AMD Alliance International (AMDAI), World Blind Union (WBU) and the International Agency for the Prevention of Blindness (IAPB).

An AMD campaign has been launched by the AMD Alliance International (AMDAI), World Blind Union (WBU) and the International Agency for the Prevention of Blindness (IAPB).

The strategy aims to provide tools for healthcare practitioners and local organisations to raise awareness of AMD to the general public.

Narinder Sharma, CEO of AMDAI, commented, "We all have a role in preventing AMD and other eye diseases. The toolkit we are launching today at our Regional EU meeting in Rome should in the first place help local organisations and healthcare practitioners develop awareness-raising initiatives for older people who are at higher risk of developing AMD, but also their friends, relatives and carers."

Alan Suttie, Chairman of World Blind Union’s Elderly Working Group and Coordinator of the European Elderly Blind Network, added, "Both NGOs and governments need to recognise the growth in age related sight loss and plan appropriate interventions. This toolkit will help them understand the challenge and plan necessary services."

The toolkit can be found by clicking here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.